Current Heart Failure Reports最新文献

{"title":"Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis.","authors":"Artrish Jefferson, Priyanka Narvekar, Bethany Roehm, Robert Toto, Lori Roth, Justin L Grodin","doi":"10.1007/s11897-026-00754-z","DOIUrl":"10.1007/s11897-026-00754-z","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of progressive cardiomyopathy that is characterized by the accumulation of misfolded transthyretin protein within the myocardium. Cardiorenal dysfunction is common among patients with ATTR-CM, and its presence is associated with worse outcomes. As such, monitoring kidney dysfunction has important implications for disease prognostication. There remains an unmet need to better characterize renal biomarkers to enhance risk stratification and assessment of treatment response in affected patients. The goal of this review is to detail how cardiorenal dysfunction influences the clinical natural history of ATTR-CM and how it may be modified by treatment. RECENT FINDINGS: An increasing body of evidence has evaluated the usefulness of various renal biomarkers in ATTR-CM. Beyond traditional measures such as estimated glomerular filtration rate(eGFR), measures of albuminuria, cystatin C, and uromodulin may better reflect glomerular and tubular vulnerability, while congestion related measures such as outpatient diuretic intensification may better capture disease trajectory. Emerging data also suggest that disease modifying therapies and supportive treatments may influence renal function over time. Cardiorenal biomarkers in ATTR-CM may provide insight into the evolving disease biology and the interplay between cardiac dysfunction and kidney injury. As disease modifying therapies become more widely used, incorporating dynamic renal measures (including eGFR trajectories and albuminuria) may refine prognostic precision and support longitudinal assessment of treatment effect. </p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13021810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevention of Heart Failure Risk Assessment and Early Intervention along the Cardiovascular Continuum.","authors":"Elisa Grossmann, Hannah-Lou Schilling, Christina Magnussen","doi":"10.1007/s11897-026-00751-2","DOIUrl":"10.1007/s11897-026-00751-2","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Heart failure (HF) is a complex clinical syndrome that develops as the final common manifestation of diverse cardiovascular disorders along a variety of different pathophysiological pathways. The trajectory towards HF is set decades earlier by a combination of non-modifiable risk factors and a substantial number of principally modifiable risk factors. Conceptualizing HF prevention as a continuum — from primordial prevention to tertiary prevention — highlights how consistently these factors determine and drive the risk to develop HF. Early at-risk and pre-HF stages therefore represent the most appropriate window for effective prevention, yet they are still underrated and under-recognized in clinical practice. RECENT FINDINGS: A broad array of modifiable risk factors, together with echocardiographic and laboratory markers, are involved in disease progression. Combining these domains may optimize risk stratification and enable more targeted prevention efforts. The rapidly evolving heart failure pandemic, largely driven by the rising prevalence of conditions that are to a substantial extent attributable to modifiable risk factors, poses an enormous burden on health systems worldwide. In consequence, enhanced global awareness, comprehensive assessment and more effective control of modifiable risk factors are urgently needed to prevent HF. A multidimensional risk assessment approach could facilitate early identification and timely intervention to prevent progression to symptomatic HF. </p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-enhanced Electrocardiography for Heart Failure Screening and Risk Stratification.","authors":"Lovedeep S Dhingra, Philip M Croon, Bruno Batinica, Arya Aminorroaya, Aline F Pedroso, Rohan Khera","doi":"10.1007/s11897-026-00748-x","DOIUrl":"10.1007/s11897-026-00748-x","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Heart failure (HF) remains a major public health challenge, often diagnosed only after symptom onset. This review describes how artificial intelligence-enhanced electrocardiography (AI-ECG) can support scalable HF screening and risk stratification across diverse settings. We also identify priorities for clinical implementation and future research. RECENT FINDINGS: AI-ECG augments conventional ECG interpretation by detecting subtle structural and functional abnormalities not apparent on visual inspection. Across cohorts, models using 12-lead ECG waveforms, ECG images, and wearable single-lead recordings identify HF precursors and predict new-onset HF risk with performance comparable to established risk scores. AI-ECG-enabled strategies can be cost-effective, particularly when deployed opportunistically in routine care or targeted community programs. AI-ECG leverages the ubiquity of ECG testing to provide a practical platform for HF risk assessment and to guide confirmatory imaging, risk factor surveillance, and therapy decisions. Realizing this potential will require interoperable ECG standards, prospective validation, regulatory oversight, and performance monitoring for safe, equitable integration into HF care pathways. </p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endomyocardial Biopsy Revisited: Diagnostic Value and Expanding Roles in Cardiac Amyloidosis.","authors":"Stéphanie K Schwarting, Fabian Aus dem Siepen","doi":"10.1007/s11897-026-00749-w","DOIUrl":"10.1007/s11897-026-00749-w","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Cardiac amyloidosis (CA) results from myocardial infiltration by misfolded amyloidogenic proteins and represents a heterogeneous group of diseases with distinct prognostic and therapeutic implications. While transthyretin amyloidosis (ATTR) and immunoglobulin light-chain amyloidosis (AL) account for the majority of clinically relevant cases, several rarer amyloid subtypes with cardiac involvement have been described.This review focusses on the role of EMB in CA, highlights its diagnostic andprognostic value, discusses procedural considerations, and outlines emergingperspectives, including its potential role in phenotyping amyloid clearance andassessing treatment response in the era of novel disease-modifying therapies. RECENT FINDINGS: Over the past decade, diagnostic algorithms have shifted from predominantly invasive approach toward non-invasive imaging, particularly bone scintigraphy, which enables reliable diagnosis of ATTR in selected patients. However, important limitations remain. Non-invasive strategies may be insufficient in early disease stages, in the presence of monoclonal gammopathy, or in rare amyloid subtypes, where definitive amyloid typing is required. In these situations, EMB continues to play a central role. Additionally, EMB allows detailed assessment of amyloid burden and myocardial. Recent studies further demonstrate that beyond its diagnostic value, EMB also offers prognostic information, as higher amyloid load and inflammatory infiltration have been associated with adverse outcomes. Procedural risks appear acceptable when EMB is performed in experienced centers, although data on optimal biopsy strategies remain limited. In the era of emerging disease-modifying therapies, EMB may also gain an increasing relevance for disease phenotyping, assessment of amyloid clearance, and evaluation of treatment response. Despite major advances in non-invasive imaging, EMB provides the highest diagnostic accuracy in selected patients with suspected CA, enabling definitive amyloid typingand comprehensive myocardial tissue characterization that may contribute to refined disease phenotyping and the assessment of treatment response. </p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12987900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets.","authors":"Ellaline Cami, Eline Verghote, Emily Pecetto, Arantxa González, Ebba Brakenhielm, Elizabeth Av Jones, Vanessa Van Empel","doi":"10.1007/s11897-026-00745-0","DOIUrl":"10.1007/s11897-026-00745-0","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Physical Activity Following Heart Failure in Humans and Animal Models: A Scoping Review.","authors":"Akinori Kaneguchi, Mahiro Fukunaga, Takuya Umehara","doi":"10.1007/s11897-026-00741-4","DOIUrl":"10.1007/s11897-026-00741-4","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers as Clinical Endpoints in Hypertrophic Cardiomyopathy Clinical Trials.","authors":"Sadia Tanami, Ahmad Masri","doi":"10.1007/s11897-026-00743-2","DOIUrl":"10.1007/s11897-026-00743-2","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Personalized Heart Failure Management: Integrating Biomarkers and Multimodal Monitoring Strategies.","authors":"Youssra Allach, Mylène Barry-Loncq de Jong, Jasper J Brugts","doi":"10.1007/s11897-026-00742-3","DOIUrl":"10.1007/s11897-026-00742-3","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Fatty Acid Binding Protein (I-FABP) in Heart Failure: A Comprehensive Review of its Role as a Biomarker and Mediator in Cardiac Dysfunction.","authors":"Tanisha Mishra, Giorgi Chilingarashvili, Dhanush Kolli, Priyanka Vatsavayi, Dhruvi Modi, Sruthi Venugopalan, Sashwath Srikanth, Rupak Desai","doi":"10.1007/s11897-026-00747-y","DOIUrl":"10.1007/s11897-026-00747-y","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Atrial Fibrillation in Heart Failure: Uncovering Therapeutic Targets in the Atrial Substrate.","authors":"Danish Sultan, Bianca J J M Brundel","doi":"10.1007/s11897-026-00744-1","DOIUrl":"10.1007/s11897-026-00744-1","url":null,"abstract":"","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}